Table I.
Comparisons of basic clinical characteristics and fertility treatment-related features between vaccinated and unvaccinated groups.
| Vaccinated group (n = 502) | Unvaccinated group (n = 1589) | t/Z/X2 | P | |
|---|---|---|---|---|
| Age (years) | 32.43 ± 3.97 | 32.70 ± 4.40 | −0.550 | 0.582 |
| Infertility duration (years) | 5 (2, 8) | 4 (0.5, 8) | −4.084 | <0.001 |
| AMH (ng/ml) | 4.93 (0.16, 9.70) | 4.65 (0.43, 8.87) | −1.146 | 0.145 |
| Total AFC | 22 (8, 36) | 22 (11, 33) | −0.094 | 0.925 |
| BMI (kg/m2) | 21.74 (17.55, 25.93) | 21.45 (17.26, 25.64) | −0.220 | 0.826 |
| Type of infertility % (n) | 2.523 | 0.112 | ||
| Primary | 42.0% (211) | 45.9% (729) | ||
| Secondary | 58.0% (291) | 53.7% (853) | ||
| Causes of infertility % (n) | 7.273 | 0.296 | ||
| Male | 10.4% (52) | 11.4% (181) | ||
| Tubal factors | 43.6% (219) | 37.7% (599) | ||
| Ovulatory disorder | 7.57% (38) | 8.37% (133) | ||
| Endometriosis | 2.8% (14) | 2.5% (39) | ||
| Unexplained infertility | 10.4% (52) | 10.3% (164) | ||
| Mixed factors | 20.5% (103) | 24.9% (395) | ||
| PGT | 4.8% (24) | 4.8% (76) | ||
| Indications of PGT | 5.172 | 0.075 | ||
| PGT-A | 25.0% (6) | 27.6% (21) | ||
| PGT-M | 54.2% (13) | 30.3% (23) | ||
| PGT-SR | 20.8% (5) | 42.1% (32) | ||
| COS cycle number | 6.193 | 0.013 | ||
| First cycle | 86.5% (434) | 90.4% (1436) | ||
| Second cycle | 13.5% (68) | 9.6% (153) | ||
| COS protocols % (n) | 8.528 | 0.014 | ||
| Antagonist | 66.9% (336) | 70.7% (1123) | ||
| Agonist | 29.9% (150) | 24.2% (385) | ||
| Others | 3.2% (16) | 5.1% (81) | ||
| Endometrial preparation protocol | 9.135 | 0.028 | ||
| Natural cycle | 23.9% (120) | 18.8% (299) | ||
| HRT cycle | 70.1% (352) | 72.3% (1149) | ||
| GnRHa + HRT cycle | 5.4% (27) | 7.9% (125) | ||
| Stimulation cycle | 0.6% (3) | 1.0% (16) | ||
| Endometrial thickness (mm) | 8.6 (6.4, 10.8) | 8.7 (6.7, 10.7) | −1.135 | 0.257 |
| Endometrial type | 3.106 | 0.212 | ||
| Type A | 42.0% (211) | 45.9% (729) | ||
| Type B | 57.6% (289) | 53.5% (850) | ||
| Type C and others | 0.4% (2) | 0.2% (3) | ||
| Fertilization type | 1.591 | 0.451 | ||
| IVF | 80.5% (404) | 77.9% (1238) | ||
| ICSI | 15.7% (79) | 18.1% (288) | ||
| IVF + ICSI | 3.8% (19) | 4.0% (63) | ||
| Number of embryos for transfer | 5.252 | 0.022 | ||
| N = 1 | 64.1% (322) | 69.6% (1106) | ||
| N = 2 | 35.9% (180) | 30.4% (483) | ||
| Embryo stage | 0.010 | 0.920 | ||
| Cleavage | 20.1% (101) | 20.3% (323) | ||
| Blastocyst | 79.9% (401) | 79.7% (1266) | ||
| Day 3 embryo# | 20.97% (143/682) | 22.88% (474/2072) | 1.077 | 0.584 |
| Day 5 embryo | 56.01% (382/682) | 54.73% (1134/2072) | ||
| Others | 23.02% (157/682) | 22.39% (464/2072) | ||
| Number of top-quality embryos for transfer | 18.085 | <0.001 | ||
| N = 0 | 24.5% (123) | 17.4% (276) | ||
| N = 1 | 59.4% (298) | 69.4% (1102) | ||
| N = 2 | 16.1% (81) | 13.3% (211) |
AMH, anti-Mullerian hormone; AFC, antral follicle counting; COS, controlled ovarian stimulation; PGT, preimplantation genetic test; PGT-A, PGT for aneuploidies; PGT-M, PGT for monogenic; PGT-SR, PGT for chromosome structural rearrangements; NA, not available/applicable; HRT, hormonal replacement therapy.
#
Proportions of Day 3, Day 5 embryos and others were calculated based on total number of embryos transferred. Values are mean ± SD; median (Quartile1, Quartile3) or percent (n).